<?xml version='1.0' encoding='utf-8'?>
<document id="23651023"><sentence text="Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment."><entity charOffset="101-114" id="DDI-PubMed.23651023.s1.e0" text="acenocoumarol" /></sentence><sentence text="The objective of this study was to investigate the impact of CYP2C9 polymorphisms and drug-drug interactions on the risk of overanticoagulation in patients treated with acenocoumarol, a vitamin K antagonist"><entity charOffset="169-182" id="DDI-PubMed.23651023.s2.e0" text="acenocoumarol" /><entity charOffset="186-195" id="DDI-PubMed.23651023.s2.e1" text="vitamin K" /><pair ddi="false" e1="DDI-PubMed.23651023.s2.e0" e2="DDI-PubMed.23651023.s2.e0" /><pair ddi="false" e1="DDI-PubMed.23651023.s2.e0" e2="DDI-PubMed.23651023.s2.e1" /></sentence><sentence text="" /><sentence text="A prospective observational study was performed on patients starting acenocoumarol (n = 115)"><entity charOffset="69-82" id="DDI-PubMed.23651023.s4.e0" text="acenocoumarol" /></sentence><sentence text=" CYP2C9 genotypes were assessed" /><sentence text=" Data on International Normalized Ratio, comedications and doses of acenocoumarol were collected during the first 35 days of therapy"><entity charOffset="68-81" id="DDI-PubMed.23651023.s6.e0" text="acenocoumarol" /></sentence><sentence text=" Overanticoagulation was defined as the occurrence of at least one International Normalized Ratio â‰¥4" /><sentence text="" /><sentence text="The presence of a CYP2C9 inhibitor or a CYP2C9 polymorphisms statistically increased the risk of overanticoagulation (hazard ratio [HR]: 2" /><sentence text="8, p &lt; 0" /><sentence text="001 and HR: 1" /><sentence text="7, p = 0" /><sentence text="04, respectively)" /><sentence text=" The presence of CYP2C9 polymorphisms almost tripled the risk of overanticoagulation (HR: 2" /><sentence text="91, p = 0" /><sentence text="01) in the presence of a clinically significant drug-drug interaction" /><sentence text="" /><sentence text="These findings support the fact that CYP2C9 genotyping could be useful to identify patients requiring closer monitoring, especially when a drug-drug interaction is expected" /><sentence text="" /></document>